The CDCN's highest priority to begin was to assemble the top global experts onto a Scientific Advisory Board that sets the overall direction and prioritizes research. Currently, the CDCN includes 32 members representing eight countries, including the United Kingdom, United States of America, Brazil, Norway, Japan, France, New Zealand, and China.
Corey Casper, MD, MPH is an Associate Professor of Medicine and Global Health at the University of Washington as well as the Director of the UCI/Hutchinson Center Cancer Alliance and the Scientific Program on AIDS-Associated Malignancies and Infections at the Fred Hutchinson Cancer Research Center. He is an Infectious Disease physician and has a weekly Castleman clinic that cares for more than 100 patients. His research interests are in HHV-8, MCD, HIV-related cancer, and cancer epidemiology.
Amy Chadburn MD, FCAP, is a professor of pathology and medical director of the Immunohistochemistry laboratory at Cornell University. Amy’s research has primarily been related to lymphomas and lymphoid lesions occurring in immunodeficient individuals. She has studied and characterized Castleman-like pathology and phenotype changes since residency.
Shanmuganathan Chandrakasan, MD, is an Assistant Professor at Children's Healthcare of Atlanta, Emory University. Shan has seen over a dozen cases of Castleman disease in pediatric patients and is leading the CDCN's effort to better understand pediatric Castleman disease through collaboration with other clinicians.
Angela Dispenzieri, MD, is a Professor of Laboratory Med/Pathology and Medicine at the Mayo Clinic. Her major research interest involves plasma cell disorders including primary systemic amyloidosis, POEMS syndrome, multiple myeloma, CD, and cryoglobulinemia. She also conducts clinical research involving hematopoietic stem cell transplantation and oncolytic viral therapy. She recently published one of the largest case series of MCD patients in the American Journal of Hematology.
Ahmet Dogan, MD, is Chief of the Hematopathology Service at Memorial Sloan Kettering Cancer Center, a board-certified pathologist, and an internationally recognized leader in hematopathology. His current research interests include lymphoma, plasma cell disorders, and diagnostic techniques for hematopathology such as cytogenetic analysis, genomics, and proteomics. His previous work has contributed much to the understanding of the histogenesis of lymphomas, MALT lymphomas, and T cell lymphomas in particular.
Kojo Elenitoba-Johnson, MD, is Professor of Pathology and Laboratory Medicine at the University of Pennsylvania.
David Fajgenbaum, MD, MBA, MSc, is the co-founder & Executive Director of the CDCN and has recently published a recent comprehensive review article on idiopathic MCD in the journal, Blood. Prior to co-founding the CDCN, Dr. Fajgenbaum co-founded and served as Board Chair for National Students of AMF, a US-based non-profit organization, for 8 years.
Alexander Fossa, MD, PhD, is senior consultant in the Department of Oncology at the Norwegian Radium Hospital and Oslo University Hospital. He is the primary treating physician of Castleman disease in his region, has a keen interest in Castleman disease (as one of the first patients he treated as a resident had MCD), and was an investigator on the Siltuximab study.
Makota Ide, MD, PhD, is a vice chief director in the Department of Hematology at Takamatsu Red Cross Hospital in Japan. He has over 20 years experience in the diagnosis and treatment of Castleman disease and has published several articles about CD, including the use of rituximab and steroid therapy in HIV-negative MCD.
Elaine Jaffe, MD, is the Head of Hematopathology Section at the National Cancer Institute (NIH). She has conducted pioneering studies related to the classification of malignant lymphomas and has led an international effort for consensus among clinicians and pathologists. Her work focuses on lymphomas as tumors of the immune system. Using a combination of immunophenotypic, genomic and genetic approaches, her group is examining the pathogenesis of lymphomas, mechanisms of transformation, and signaling pathways involved in control of cellular proliferation and differentiation.
Raj Jayanthan, MD, is a Pediatrics Resident at Texas Children's Hospital and also a patient with HHV-8-negative multicentric Castleman disease.
Dermot Kelleher, MD, FRCPI, FRCP, FMedSci, FTCD, is Dean of the Faculty of Medicine and Vice President of Health at Imperial College London. His research has focused on the cell biology of immune responses to infectious diseases both in terms of basic lymphocyte function and in relation to mucosal immunology. Dr. Kelleher is a founding member of Opsona Therapeutics, a spinout company at Trinity College Dublin based on development of therapeutic technologies founded on innate immunity and T-regulatory cells.
Vera P. Krymskaya, PhD, MBA, is Associate Professor of Medicine at the Pulmonary, Allergy, and Critical Care Division at the University of Pennsylvania Perelman School of Medicine. Dr. Krymskaya is an expert in basic research and translational medicine in rare lung diseases, including sporadic pulmonary lymphangioleiomyomatosis (LAM), Tuberous Sclerosis (TS)-associated LAM, Birt-Hogg-Dube (BHD), pulmonary arterial hypertension (PAH), chronic obstructive pulmonary disease (COPD), and asthma. Dr. Krymskaya uncovered the function of tumor suppressor tuberous sclerosis complex 2 (TSC2) that paved the way for the effective treatment of patients with LAM and Tuberous Sclerosis. Dr. Krymskaya has made major contributions in the field of LAM, TS, BHD, and is nationally and internationally recognized leader in basic and translational research in these areas.
Razelle Kurzrock, MD, is Senior Deputy Center Director for Clinical Science at UC San Diego Moore’s Cancer Center. She has served as PI on more than 90 clinical trials, mainly using novel targeted molecules, several of which have gone on to FDA approval. She has studied the role of interleukin-6 in multiple cancers, and has published about 65 peer-reviewed papers on this subject. She has treated many patients with Castleman disease and has published on the use of interleukin-6 antibody and inerleukin-1 receptor antagonist in this disease.
Mary Jo Lechowicz, MD, is an Associate Professor in hematology and oncology at Emory University. Her research interests are in hematologic malignancies, and she is co-principal investigator on a national clinical trial conducted through the AIDS Malignancy Consortium to examine expression of Karposi’s Sarcoma related Herpes Virus in AIDS patients.
Megan Lim, MD, PhD, is a Professor of Pathology and Laboratory Medicine and Chief of Hematopathology at the University of Pennsylvania.
Nikhil Munshi, MD, is a Professor of Medicine at Harvard Medical School and Associate Professor of Medical Oncology at Dana-Farber Cancer Institute.
Sunita Nasta, MD, is an Associate Professor of Clinical Medicine at the University of Pennsylvania.
Eric Oksenhendler, MD, is a Professor in the department of Clinical Immunology at Hopital Saint-Louis in Paris. He has 9 years experience with registry management in Primary Immune Deficiency (> 5000 patients). He has been one of the leading experts worldwide in the elucidation and description of HHV-8-associated MCD.
Jean-Francois Rossi, MD, PhD, is a professor and Head of the department of Haematology at University Hospital – Saint-Eloi in Montpellier, France. He is a member of the INSERM unit based on B-cell diseases and immune therapy as well as in charge at the clinical level in his region for rare diseases such as plasma cell dyscrasias.
Arthur Rubenstein, MBBcH, is a Professor of Medicine at the University of Pennsylvania in the division of Endocrinology, Diabetes, and Metabolism and Dean Emeritus/Former EVP of the University of Pennsylvania School of Medicine. Dr. Rubenstein led. An internationally renowned endocrinologist, Dr. Rubenstein was part of a research team that uncovered the link between a genetic mutation in insulin causing a form of diabetes. After leading the University of Pennsylvania Health System for over 10 years, he stepped down in 2011 and served as the Interim Director of the Penn Center for Orphan Disease Research & Therapy. He is a member of the Institute of Medicine (IOM).
Jason Ruth, PhD, is the Director of Translational Research of the CDCN and a post-doctoral researcher at the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard. He is passionate about maximizing the impact that the CDCN has on patients by identifying research ideas that further understanding about Castleman Disease in a clinically meaningful way.
Steve Schey, MD, is a Professor and consultant haematologist at King's College Hospital.
David Simpson, BHB, MBChB, FRACP, FRCPA, is a consultant hematologist at North Shore Hospital in Auckland, NZ. His research interest is in myeloma and his clinical practice has a large Polynesian population in whom a pure-hyper IL-6 variant of Castlemans is more common.
Gordan Srkalovic, MD, PhD, is the Director in the Office of Clinical Trials at the Sparrow Regional Cancer Center and Clinical Associate Professor of Medicine at Michigan State University. He was an investigator on the Janssen Siltuximab study and is a member of the working group at SWOG.
Matthew Streetly, MD, is a Consultant Haematologist at King's College Hospital.
Tom Uldrick, MD, MS, is Deputy Head, Global Oncology at the Fred Hutchinson Cancer Research Center with clinical and population-based research in the field of KHSV-associated MCD, primary effusion lymphoma, and KSHV/HHV8-associated inflammatory cytokine syndrome. His major research interests are the natural history and management of virally associated malignancies that occur in the setting of HIV/AIDS and other immune disorders. He also has a strong scientific interest in applying what is known in KSHV/HHV-8-associated MCD to contribute to the field of KSHV/HHV8-negative Multicentric Castleman disease.
Peter Voorhees, MD, is an Assistant Professor in Hematology-Oncology and Clinical Researcher at UNC Comprehensive Cancer Center. His clinical interest is in hematologic malignancies with a focus on plasma cell dyscrasias. His research focuses on understanding the basis of resistance to chemotherapy in multiple myeloma and the development of therapeutic strategies that overcome chemotherapy resistance. He was an investigator on the Janssen Siltuximab study.
Frits van Rhee, MD, PhD, MRCP (UK), FRCPath, is a Professor of Medicine and Director of Clinical Research with the Myeloma Institute for Research and Therapy at the University of Arkansas. He is an Internist/ Medical Oncologist who specializes in Castleman disease, Myeloma, and Stem Cell Transplantation. He is the leader of Developmental Therapeutics project in the Myeloma Institute’s “Growth Control in Multiple Myeloma” P01 grant from the NCI and principal investigator on an R01 grant from the NCI, “Potentiating Natural Killer Cell Anti-Myeloma Effects.” He leads the “UAMS Castleman’s Research Laboratory,” which conducts some of the leading and singular basic and translational research into HIV-negative, HHV-8-negative MCD.
Raymond Wong, MBChB, MD, MRCP(UK), FHKCP, FHKAM(Medicine), is a Consultant of the Department of Medicine & Therapeutics, Prince of Wales Hospital, Hong Kong and an Honorary Clinical Assistant Professor of the Chinese University of Hong Kong. He has taken care of patients with Castleman disease for more than 10 years and was an investigator on the Janssen Siltuximab study.
David Wu, MD, PhD, is an Assistant Professor at the University or Washington and the Associate Director of UW Hematopathology. He was an investigator conducting primary central pathology review for the Siltuximab study. His research interests are in the discovery of novel diagnostic markers of hematopoietic neoplasms for diagnostic applications and the development of next-generation sequencing technologies for diagnosis and prognostication.
Kazuyuki Yoshizaki, MD, PhD, is a Professor in the Dept of Immuno-Medical Science at Osaka University, Japan. He was the principal investigator that identified IL-6 as the key cytokine in the pathogenesis of MCD (1989), found anti-IL-6R Ab improved the abnormal findings of MCD (2002), and found the mechanism of inflammatory anemia via IL-6 induced hepcidin (2010). He has treated almost 100 patients with MCD over the last 30 years; almost all that have been tested are HIV-negative and HHV-8-negative.